Protara Therapeutics Inc. (TARA)
4.70
-0.33 (-6.56%)
At close: Jan 15, 2025, 3:59 PM
4.70
0.00%
After-hours Jan 15, 2025, 05:38 PM EST
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.
The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.
Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 22, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South New York, New York United States | |
| Website | https://www.protaratx.com |
Stock Details
| Ticker Symbol | TARA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001359931 |
| CUSIP Number | 74365U107 |
| ISIN Number | US74365U1079 |
| Employer ID | 20-4580525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director |
| Patrick Fabbio M.B.A. | Chief Financial Officer |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior Vice President & Chief Scientific Operations Officer |
| Hannah Fry | Vice President, Principal Accounting Officer & Controller |
| Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Dec 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 424B5 | Filing |
| Dec 09, 2024 | 424B5 | Filing |
| Dec 05, 2024 | 8-K | Current Report |
| Nov 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |